R21/Matrix-M Malaria Vaccines
On 20th May, 2024, Pune-based Serum Institute of India (SII) shipped its first batch of the R21/Matrix-M malaria vaccine to Africa.
What is R21/Matrix-M?
- The R21//Matrix-M vaccine is the second malaria vaccine to be authorized for use in children in malaria-endemic regions, following the RTS, S/AS01 vaccine, which gained WHO recommendation in 2021.
- The vaccine has been developed through collaboration between the Jenner Institute at Oxford University and the Serum Institute of India leveraging by Novavax’s saponin-based adjuvant technology.
- R21/Matrix-M vaccine received WHO recommendation for use in children in October, 2023, followed by the announcement of its high efficacy of its Phase ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Women in Space Leadership Programme
- 2 WHO Launches First Global Framework for Pathogen Origins
- 3 Periodic Labour Force Survey
- 4 National Health Accounts Estimates for India 2020-21 & 2021-22
- 5 Impact of SBM on Infant Mortality Rates in India
- 6 Tobacco Free Youth Campaign 2.0
- 7 States & UTs to Notify Centre’s Guidelines on School Safety
- 8 Crime against Scheduled Castes and Scheduled Tribes
- 9 Mankidia Community Granted Habitat Rights in Odisha
- 10 WHO Declares Mpox a PHEIC
